Metrics as of 10/14/2026, 06:32 AM (Berlin time), refresh in progress.
Phathom Pharmaceuticals Stock
Phathom Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Steven L. Basta
- Employees
- 371
- Market cap
- $566 M
- IPO
- 25/10/2019
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid…
Phathom Pharmaceuticals stock: price history
1D
-1.8%
1W
+3.2%
1M
-16.3%
6M
-44.8%
YTD
-57.8%
1Y
-44.1%
2Y
-53.6%
5Y
-78.1%
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~39% stronger price swings than usual
Ask the agents about Phathom Pharmaceuticals
Analyst assessment of Phathom Pharmaceuticals
PRICE TARGET LOW
US$10.00
CONSENSUS
US$17.60
MEDIAN
US$20.00
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 17/08/2026
Phathom Pharmaceuticals stock metrics
P/E
-5.47
P/B
-1.7
EV/EBITDA
-15.68
RETURN ON EQUITY
5.1%
NET MARGIN
-23.7%
DEBT/EQUITY
-0.49
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
80.7%
FLOAT SHARES
65,292,701
AVG. DAILY VOLUME (30D)
1,312,438
Insider transactions (SEC)
Narula Sanjeev
Breedlove Robert Charles
Breedlove Robert Charles
Parikh Asit
Parikh Asit
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.8%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Phathom Pharmaceuticals stock
What does Phathom Pharmaceuticals do?
Phathom Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Steven L. Basta, the company employs around 371 people.
The IPO was on 25/10/2019; the stock trades on NASDAQ under the ticker PHAT.
What do analysts say about Phathom Pharmaceuticals stock?
9 analysts rate the stock, the consensus is Buy (as of 17/08/2026).
The average price target is US$17.60, ranging from US$10.00 to US$22.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Phathom Pharmaceuticals report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 39% stronger than usual.
Does Phathom Pharmaceuticals pay a dividend?
No, Phathom Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Phathom Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Phathom Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Phathom Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.